drugset
drugset / Trial / NCT05196711

A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects

NCT05196711 ↗

Phase 1 Unknown 78 enrolled Maxinovel Pty., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a First-in-Human phase I study to evaluate the safety, tolerability and pharmacokinetic characteristics of MAX-40070 in Healthy SubjectThe study will be comprised of 2 parts; Part A and Part B. Part A will be conducted at NZCR, and Part B will be conducted at both NZCR and another site(s) in China (if required). Part A will include approximately 48 participants, and Part B will include approximately 30 participants.

Timeline

Start
2022-02-28
Primary completion
2022-11-02
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MAX-40070 Unknown 0.5 % —
Subject MAX-40070 Unknown 2 % —

Indications

alopecia areata